Michael Thomas

28.3k citations
383 papers · 22.5k · 14 hit papers · h-index 63

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Brain Metastases and Treatment
    • Cancer-related molecular mechanisms research
    • Cancer Genomics and Diagnostics

Papers in

    • Lung Cancer Treatments and Mutations 149
    • Lung Cancer Diagnosis and Treatment 85
    • Brain Metastases and Treatment 17
    • Lung Cancer Research Studies 52
    • Cancer Immunotherapy and Biomarkers 34
    • Cancer survivorship and care 17

Michael Thomas

363 papers receiving 21.9k citations

Michael Thomas's Hit Papers

Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC 2025 · 45 citations
450+7+15Years since publication5001k1.5k2k2.5k

Peers

Michael Thomas
Comparison fields: 5 of 141
  • Pulmonary and Respiratory Medicine 12k
  • Cancer Research 3k
  • Oncology 4.2k
  • Pharmacy 181
  • Molecular Biology 2k
Replace Sun Young Rha with:
Sun Young Rha South Korea
Maha Hussain United States
Natasha B. Leighl Canada
Sumanta Kumar Pal United States
Karen L. Reckamp United States
Frank V. Fossella United States
Nadia Howlader United States
Tomasz M. Beer United States
Debu Tripathy United States
Nasser H. Hanna United States
Michael Thomas relative to Sun Young Rha South Korea Sun Young Rha's profile →
Citations per field
00.5×1.5×
Sun Young Rha · 1×
Citations per year

Countries citing papers authored by Michael Thomas

Since Specialization
Citations

This map shows the geographic impact of Michael Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Thomas more than expected).

Fields of papers citing papers by Michael Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Thomas. The network helps show where Michael Thomas may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Thomas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Thomas Line = papers co-authored together Michael Thomas links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 383 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Hit paper breakdown →
20132903
2
MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer
Hit paper breakdown →
20031930
3
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Hit paper breakdown →
20141251
4
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Hit paper breakdown →
20141059
5
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Hit paper breakdown →
2020743
6
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
Hit paper breakdown →
2012598
7
Early palliative care for adults with advanced cancer
Hit paper breakdown →
2017570
8
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hit paper breakdown →
2013506
9
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Hit paper breakdown →
2012496
10 2002424
11
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Hit paper breakdown →
2016402
12 2010377
13 2015340
14
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Hit paper breakdown →
2021328
15 2008266
16 2011253
17 2010243
18 1998228
19 2012179
20 2004176

About Michael Thomas

Michael Thomas is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 383 papers that have together received 22.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (149 papers), Lung Cancer Diagnosis and Treatment (85 papers), Lung Cancer Research Studies (52 papers), Cancer Immunotherapy and Biomarkers (34 papers), Palliative Care and End-of-Life Issues (29 papers), Brain Metastases and Treatment (17 papers), Cancer survivorship and care (17 papers) and Cancer Genomics and Diagnostics (17 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (12k citations), Cancer Research (3k citations), Oncology (4.2k citations), Pharmacy (181 citations) and Molecular Biology (2k citations). Michael Thomas has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Wolfgang E. Berdel, Thomas Muley, Carsten Müller‐Tidow, Hubert L. Serve, Sven Diederichs, Paul M. Schneider, Burkhard Brandt, Etmar Bulk, Ralf Metzger and Albrecht Stenzinger. Their work appears in journals such as Lung Cancer, Annals of Oncology, Journal of Thoracic Oncology, International Journal of Cancer and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact